Corneal Edema Clinical Trial
Official title:
Prospective Analysis of Loteprednol Etabonate Ophthalmic Suspension 0.25% for Prevention of Immunologic Rejection After Descemet Membrane Endothelial Keratoplasty
Verified date | September 2023 |
Source | Price Vision Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess off-label use of loteprednol etabonate 0.25% ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year after Descemet membrane endothelial keratoplasty (DMEK). Topical corticosteroids have long been the mainstay for preventing and treating cornea transplant rejection although none are specifically approved for this purpose. The rates of immunologic rejection episodes and steroid-induced ocular hypertension will be compared with the respective rates observed in earlier studies with prednisolone acetate 1% suspension, loteprednol etabonate 0.5% gel, and fluorometholone 0.1% suspension after DMEK.
Status | Completed |
Enrollment | 71 |
Est. completion date | September 5, 2023 |
Est. primary completion date | September 5, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - o At least 18 years of age - Male or female patient who had DMEK within the past 1 to 7 weeks. - Patient is able and willing to administer eye drops. - Patient is able to comprehend and has signed the Informed Consent form. - Patient is likely to complete the 11-month study duration. Exclusion Criteria: - o A history of a previous rejection episode in the study eye - A patient exhibiting intraocular inflammation. - A patient with a known sensitivity to any of the ingredients in the study medications - A patient who has a condition (i.e., UNCONTROLLED systemic disease) or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study - A patient with abnormal eyelid function. - A patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis. - Presence of any ocular disease that would interfere with the evaluation of the study treatment. However, patients with a history of cystoid macular edema, age-related macular degeneration, controlled glaucoma, corneal neovascularization, and other non-interfering comorbidities may be enrolled. - A patient with a history of non-compliance with using prescribed medication. - Patients who are pregnant or planning to become pregnant within the duration of the study |
Country | Name | City | State |
---|---|---|---|
United States | Price Vision Group | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Price Vision Group | Kala Pharmaceuticals, Inc. |
United States,
Price MO, Feng MT, Scanameo A, Price FW Jr. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial. Cornea. 2015 Aug;34(8):853-8. doi: 10.1097/ICO.0000000000000475. — View Citation
Price MO, Price FW Jr, Kruse FE, Bachmann BO, Tourtas T. Randomized comparison of topical prednisolone acetate 1% versus fluorometholone 0.1% in the first year after descemet membrane endothelial keratoplasty. Cornea. 2014 Sep;33(9):880-6. doi: 10.1097/ICO.0000000000000206. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Immunologic rejection | incidence of immunologic rejection episodes | 11 months | |
Primary | steroid-induced ocular hypertension | incidence of steroid-induced ocular hypertension | 11 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05139771 -
EndoArt® Implantation in Subjects With Chronic Corneal Edema
|
N/A | |
Enrolling by invitation |
NCT05956535 -
Air Optix® Night and Day® Aqua Therapeutic Wear
|
||
Completed |
NCT02332109 -
ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy
|
N/A | |
Completed |
NCT04498169 -
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
|
Phase 2 | |
Active, not recruiting |
NCT06041256 -
A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)
|
Phase 1/Phase 2 | |
Completed |
NCT04521140 -
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery
|
Phase 4 | |
Completed |
NCT01998568 -
The Intraocular Pressure Measured by Different Tonometers in Corneal Edema
|
N/A | |
Recruiting |
NCT04191629 -
Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema
|
Phase 1 | |
Completed |
NCT04975971 -
A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
|
||
Completed |
NCT05309135 -
A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction
|
Phase 1 | |
Completed |
NCT01853696 -
Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
|
Phase 4 | |
Completed |
NCT01244334 -
Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.
|
Phase 4 | |
Completed |
NCT05891106 -
AONDA Therapeutic Indication Study I
|
||
Active, not recruiting |
NCT04894110 -
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
|
Phase 1 | |
Completed |
NCT01387620 -
Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2%
|
Phase 4 | |
Completed |
NCT00346138 -
A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema
|
N/A | |
Completed |
NCT05271058 -
Effect of Intracameral Steroids During Phacoemulsification on the Cornea
|
Phase 3 | |
Recruiting |
NCT05626478 -
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
|
Phase 4 | |
Completed |
NCT01890252 -
Hyper-CLâ„¢ Lens (Hyper Osmotic Contact Lens) In Subjects Suffering From Corneal Edema
|
N/A | |
Not yet recruiting |
NCT00800423 -
Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema
|
Phase 3 |